Beyond The Printed Page

41. 6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing 12/14/2020

    Most of us knew that a significant amount of biopharma manufacturing had been offshored to places like China and India. However, most of us (despite Louis Garguilo having written about this as a problem rising on the horizon for years), never thought a supposed trade ally would ever actually use this as a point of leverage to try to get its way.

42. 6 Biopharma CFOs Discuss The Pandemic's Impact On The Supply Chain, Their Job And More 12/10/2020

    The first year Life Science Leader began involving finance executives in our annual outlook issue (2018) we had just one biopharmaceutical company CFO participate. This year we had eight. And while we are thrilled to have so many CFOs eager and willing to share their knowledge and perspectives, it can present a challenge for a print publication. 

43. How Will The Pandemic Impact Biopharma's Annual Kickoff? 12/7/2020

    In September, when we emailed participants for our annual finance outlook article, it still wasn’t clear if JPM would be in-person or virtual. We asked them how the pandemic might impact the whole kickoff week, and although we now know the plan is to be 100% virtual, we thought their insights would be better shared sooner rather than later. 

44. What Do Biopharma CFOs Think About The Market's Future? 12/3/2020

    For this year’s annual finance outlook article, appearing in Life Science Leader’s December 2020 issue, we had 10 financial executives take part — 8 being biopharmaceutical company CFOs. As we couldn’t fit all of the wisdom offered into this year’s print edition, we share it here via our Beyond The Printed Page online section of the magazine.

45. Politics And The Pandemic — Where Are They Taking Biopharma? 11/30/2020

    Seventeen top executives of companies representing the entrepreneurial edge of biopharma innovation answer our call for feedback on how the COVID pandemic and the politics surrounding it could affect their futures and the industry.

46. What Do 6 Biopharmaceutical Manufacturing Execs Expect For 2021 And Beyond? 11/30/2020

    For this installment of Beyond The Printed Page, we have six biopharmaceutical industry manufacturing executives sharing their perspectives toward helping their peers prepare for 2021 and beyond.

47. 9 Biopharma CEOs On COVID-19 Induced Trend Opportunities 11/23/2020

    This year’s CEO outlook article in Life Science Leader’s annual outlook issue, published in December, has 15 CEOs taking part! Some members of this year’s CEO class were posed a question around what COVID-19 induced trends they envisioned sticking around well beyond the end of this pandemic. 

48. What COVID-19 Causations Will Continue In 2021 And Beyond? 11/16/2020

    Unprecedented. That’s the word used ad nauseam to describe much of what we experienced in 2020. And while many of these moves were unprecedented at the time, now that they’ve been done, they now serve as a precedent. This makes you wonder just how many COVID-19 causations will continue into 2021 and beyond?

49. Henri Termeer – A Much Missed Mentor 10/26/2020

    Chief Editor Rob Wright talks about the last time he spoke with Henri Termeer, who was a mentor to Paula Ragan, Ph.D., cofounder and CEO of X4 Pharmaceuticals (subject of the November 2020 cover feature in Life Science Leader).

50. Execs Weigh In On Presidential Politics Impacting Biopharma 10/23/2020

    Nine executives share their thoughts on what impact will be had on the biopharmaceutical industry by the outcome of the upcoming U.S. election.